Elinogrel is the only direct acting, reversible, i.v. and oral P2Y12 ADP receptor antagonist in clinical development. Inhibiting the P2Y12 ADP receptor on platelets has been proven to prevent thrombosis and subsequent heart attacks. Because of its properties, elinogrel has the potential to provide significant clinical advantages compared to Plavix(R)* (clopidogrel), the current standard of care, and to newer agents in development, such as prasugrel, by lowering the risk of ischemic events due to clot formation and reducing the risk of bleeding. In addition, elinogrel is the only compound in development that can be administered intravenously in the hospital and orally in the chronic setting.
In Portola's clinical studies to date with the i.v. and oral formulations, results showed that elinogrel appeared to be well-tolerated without serious adverse events and demonstrated predictable, dose-dependent platelet inhibition. At the American Heart Association Scientific Sessions in November 2008, Dr. Paul Gurbel presented data that showed elinogrel overcomes high platelet reactivity, which is a known marker for adverse ischemic events in patients non-responsive to clopidogrel.
In December 2008, Portola initiated patient enrollment in INNOVATE-PCI, an 800-patient Phase 2 clinical trial of the i.v. and oral forms of elinogrel in a broad group of patients undergoing non-urgent percutaneous coronary intervention. Portola, together with Novartis, plans to further develop elinogrel to treat patients with acute coronary syndromes and broadly in patients with a prior heart attack or stroke, and those with peripheral vascular disease.
* Plavix(R) is
|SOURCE Portola Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved